RxDoctor Payments Data

Christopher Hartigan

Family · Columbia, MONPI 1336132091

Payments from drug & device makers

$1,140in general payments, 2019–2025

Across 75 payments — averaging $15.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$298
  • AstraZeneca$140
  • Amgen$122
  • Merck$116
  • Novo Nordisk$62
  • Pfizer$59
  • plus $344 from 13 others

What the payments were for

  • Food & beverage$1,12699%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,140 in reported general payments places this provider in the 70th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Medicare billing

Part B allowed, 2024
$1,685
Medicare patients
51
Services billed
81

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide241$232,529
FarxigaDapagliflozin Propanediol331$219,324
OzempicSemaglutide94$99,992
JardianceEmpagliflozin69$51,021
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr99$49,603
EliquisApixaban57$43,213
MounjaroTirzepatide34$36,108
LinzessLinaclotide61$32,648
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$27,673
Tresiba Flextouch U-200Insulin Degludec23$27,535
QuliptaAtogepant23$26,270
Combivent RespimatIpratropium/Albuterol Sulfate49$24,108
Invega SustennaPaliperidone Palmitate12$22,246
JanuviaSitagliptin Phosphate18$20,148
VascepaIcosapent Ethyl53$18,631

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$27$268,637275 claims
AstraZenecaFarxiga, Symbicort$140$227,981368 claims
Novo NordiskOzempic, Rybelsus$62$118,572114 claims
GSKAnoro Ellipta, Trelegy Ellipta$14$77,276141 claims
AbbVieLinzess, Qulipta, Ubrelvy$298$73,44398 claims
PfizerEliquis, Zavzpret, Abrysvo$59$60,70884 claims
Johnson & JohnsonInvega Sustenna, Invokana$17$35,48038 claims
MerckJanuvia$116$20,14818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,812 family providers in Missouri.

Other family in Columbia

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →